Moderna, Goldman Sachs
Moderna Stock Falls on Vaccine Revenue Concerns
Shares of Moderna Inc. (NASDAQ: MRNA) are down 3.2% in premarket trading after a bear note from Goldman Sachs. The firm lowered its rating on MRNA to "neutral" from "buy," and nearly halved its price target from $99 to $51, citing ongoing vaccine revenue challenges.
Based on its share price, down 75% in the last three years, it's easy to write off Moderna (NASDAQ: MRNA) as a biotech ...
The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...
The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.
No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...
10don MSN
While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...
Evercore ISI lowered the firm’s price target on Moderna (MRNA) to $50 from $60 and keeps an In Line rating on the shares. The firm is updating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback